Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 1;8(10):12390-9.
eCollection 2015.

Effect of a new drug releasing system on microencapsulated islet transplantation

Affiliations

Effect of a new drug releasing system on microencapsulated islet transplantation

Binjie Lu et al. Int J Clin Exp Pathol. .

Abstract

Objective: This study aimed to develop a novel release system for grafted islets.

Materials and methods: A graphene oxide-FTY720 release system was constructed to test the drug loading and releasing capacity. The recipient rats were divided into four groups as following: Experiment group A (EG A) and B (EG B); Control group A (CG A) and B (CG B). In each group, (2000 ± 100) IEQ microencapsulated islets were implanted into the abdominal cavity of the recipients with oral FTY720, local graphene oxide-FTY720 injection, without immunosuppressants, and with graphene oxide-saturated solution respectively. We detected the immunological data, the blood glucose level, and pericapsular overgrowth to show the transplantation effect.

Results: 31% of adsorptive FTY720 was released within 6 h, and 82% of FTY720 was released within 48 h. From day 5 to 8, the amount of PBL in EG B was significantly less than those in EG A (P<0.01). The CD3+ and CD8+ T lymphocytes were suppressed 3 days longer in EG B than in EG A. On day 19 posttransplantation, the blood glucose level in EG B was much lower than that in EG A (P<0.01). On the same day, pericapsular overgrowth was grade I in EG B, grade II in other groups.

Conclusions: Graphene oxide-FTY720 complex showed a drug releasing effect. Local application of graphene-FTY720 releasing system could decrease the amount of peripheral blood lymphocytes (PBL) and the percentage of CD3 and CD8 T lymphocytes in blood for longer time than oral drug application. This releasing system could achieve a better blood glucose control.

Keywords: Islet transplantation; graphene oxide; immunosuppressants; microencapsulation; overgrowth.

PubMed Disclaimer

Figures

Figure 1
Figure 1
FTY720 release changing with time. Experiments performed five times.
Figure 2
Figure 2
Activity detection of microencapsulated islets. A. DTZ stain of islets (100×). B. SYTO-green and EB stain of islets (100×). C. Microencapsulated islets (150×). A. The red stain represented the islets; B. The green stain represented live islets, red stain represented dead islets; C. 1-3 islets were encapsulated in one capsule.
Figure 3
Figure 3
A: ΔP<0.01 EG B vs. EG A; *P<0.01 EG B vs. CG B; B: ΔP<0.01 EG B vs. EG A; *P<0.01 EG B vs. CG B; C: ΔP<0.05 EG B vs. EG A; *P<0.01 EG B vs. CG B.
Figure 4
Figure 4
Changes in blood glucose of recipients after transplantation, ΔP<0.01 EG B vs. EG A.; *P<0.01 EG B vs. CG B.
Figure 5
Figure 5
A. Grade of overgrowth, from 0-III grade under light microscope (150×). B. Comparison of the pericapsular overgrowth in both EGs on day 19 posttransplantation (400×). (In each group, two recipients were analyzed) the black arrows represent the yellow stained T lymphocytes, and the white arrows represent the capsules.

Similar articles

Cited by

References

    1. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980;210:908–910. - PubMed
    1. Alejandro R, Barton FB, Hering BJ, Wease S Collaborative Islet Transplant Registry Investigators. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation. 2008;86:1783–8. - PubMed
    1. Kobayashi T, Arefanian H, Harb G, Tredget EB, Rajotte RV, Korbutt GS, Rayat GR. Prolonged survival of microencapsulated neonatal porcine islet xenografts in immune-competent mice without antirejection therapy. Cell Transplant. 2008;17:1243–1256. - PubMed
    1. Figliuzzi M, Plati T, Cornolti R, Adobati F, Fagiani A, Rossi L, Remuzzi G, Remuzzi A. Biocompatibility and function of microencapsulated pancreatic islets. Acta Biomater. 2006;2:221–227. - PubMed
    1. Orive G, Tam SK, Pedraz JL, Halle JP. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials. 2006;27:3691–3700. - PubMed

MeSH terms